Table 1 Demographics, clinical features, and MRI findings in the various subject groups.
From: White matter and nigral alterations in multiple system atrophy-parkinsonian type
First cohort | Second cohort | |||||
|---|---|---|---|---|---|---|
HCs | PD | MSA-P | HCs | PD | MSA-P | |
Participants, n | n = 20 | n = 19 | n = 21 | n = 24 | n = 17 | n = 10 |
Age, years | 62.8 ± 4.7 | 63.1 ± 8.1 | 62.5 ± 11.7 | 65.8 ± 6.5 | 63.2 ± 10.2 | 65.3 ± 9.5 |
Male, % (n) | 40.0% (8/20) | 35.0% (7/20) | 40.0% (8/20) | 54.2% (13/24) | 58.8% (10/17) | 70.0% (7/10) |
Disease duration, years | NA | 5.2 ± 1.6 | 3.4 ± 1.7* | NA | 4.7 ± 2.1 | 3.3 ± 0.95* |
Hoehn & Yahr stage | NA | 2.1 ± 0.8 | 3.2 ± 0.7** | NA | 1.9 ± 0.7 | 3.0 ± 0.8** |
MDS-UPDRS part 3 | NA | 15.3 ± 11.3 | 40.1 ± 16.0** | NA | 18.8 ± 13.3 | 56.1 ± 15.3** |
UMSARS part 2 | NA | NA | 21.2 ± 8.7 | NA | NA | 27.9 ± 7.3 |
Levodopa equivalent daily dose, mg | NA | 677.0 ± 362.6 | 658.0 ± 310.0 | NA | 662.5 ± 509.1 | 859.1 ± 480.2 |
RBD present, % (n) | NA | 36.8% (7/19) | 47.6% (10/21) | NA | 23.5% (4/17) | 40.0% (4/10) |
MRI findings | ||||||
Pontine cross sing, % (n) | NA | 0% (0/19) | 9.5% (2/21) | NA | 0% (0/17) | 0.0% (0/10) |
vertical hyperintensity line in the pons, % (n) | NA | 0% (0/19) | 42.1% (8/21)* | NA | 0% (0/17) | 10.0% (1/10) |
Cerebellar atrophy, % (n) | NA | 0% (0/19) | 71.4% (15/21)** | NA | 0% (0/17) | 80.0% (8/10)** |
Middle cerebellar peduncle-sign, % (n) | NA | 0% (0/19) | 4.8% (1/21) | NA | 0% (0/17) | 0.0% (0/10) |
Putaminal slit, % (n) | NA | 0% (0/19) | 85.7% (18/21)** | NA | 0% (0/17) | 90.0% (9/10)** |
